Possible Female Sexual Dysfunction Drug

Ukmedix is very excited by new research that has been done with a heart drug called Candoxatril which may have properties that could help women who suffer from female sexual dysfunction. The study recently carried out shows that when the drug was slightly modified it could actually boost the blood flow to the vagina area when it was used in animal testing.

Further research is in the pipeline and if the drug can be shown to help women the possibilities for this drug are extremely exciting. It is thought that more women than men suffer from sexual disorders and so the commercial potentials of this drug are enormous. It is thought that as many as 40% of all women suffer from Female Sexual Dysfunction (FSD).

Interestingly enough Candoxatril was the subject of clinical trials in the 90's to treat people with heart failure and like Viagra that was originally a treatment for angina it has found a possible new use for people suffering from sexual dysfunction.

Candoxatril works by targeting the levels of vasoactive intestinal peptide (VIP) that regulate the blood flow into the vagina and it is commonly known that a lowered blood flow to the vagina is a key factor in sufferers of female sexual dysfunction. In fact Candoxatril actually blocks the enzyme NEP that degrades the VIP levels in the body.

In the study the molecular structure of the heart drug Candoxatril was slightly altered so that it would work purely for female sexual dysfunction and when the drug was tested on animals at Pfizer's Global Research and Development Centre in the United Kingdom it was seen that the compound blocked NEP very quickly. As the drug has only been tested on animals the actual results on humans is not known but it is probable that some effects will be experienced.